Overview
- Novo’s shares have risen about 35% from a March low as the company shifts to a more aggressive commercial stance backed by its oral Wegovy pill.
- Prescription data from IQVIA shows oral Wegovy demand stronger than many analysts expected and higher than Lilly’s oral Foundayo, though some Foundayo channels may be undercounted.
- Eli Lilly still holds a clear lead in injectables, with Zepbound’s weekly prescriptions running more than double Novo’s injectable Wegovy in recent months.
- Novo has filed a U.S. federal false-advertising suit against Lilly over efficacy comparisons that exclude Novo’s higher-dose Wegovy, and Lilly has denied the claims.
- Investors and analysts say Q2 results will test whether Novo’s recovery can stick, with risks including U.S. pricing pressure, later generic competition and the company’s recent failed heart-disease trial.